• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

肿瘤浸润淋巴细胞（TILs）与抗 PD-1 治疗：PDL1 阴性转移性宫颈癌的一种替代联合治疗方法。

TILs and Anti-PD1 Therapy: An Alternative Combination Therapy for PDL1 Negative Metastatic Cervical Cancer.

机构信息

Department of Obstetrics, Luoyang Central Hospital Affiliated to Zhengzhou University, Luoyang 471009, China.

出版信息

J Immunol Res. 2020 Sep 7;2020:8345235. doi: 10.1155/2020/8345235. eCollection 2020.

DOI:10.1155/2020/8345235
PMID:32964058
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7492938/
Abstract

BACKGROUND

We investigated the efficacy of TILs and anti-PD1 combination therapy in patients with metastatic cervical cancer with low MSI expression and PDL1-negative.

METHODS

A total of 80 patients were put on TILs and anti-PD1 combination therapy, and the progression-free survival time (PFS) and overall survival time (OS) were assessed by Kaplan-Meier analysis. Univariate and multivariate analyses were performed to identify factors that could predict the prognosis of metastatic cervical cancer in the previously described patients.

RESULTS

The objective response rate was 25%, whereas the mPFS and mOS were 6.1 and 11.3 months, respectively. The therapeutic efficacy was influenced by the characteristics of TILs, infection with HPV, and development of fever just after the therapy.

CONCLUSION

Overall, our results show that the combination therapy of TILs and anti-PD1 significantly improves the prognosis of metastatic cervical cancer.

摘要

背景

我们研究了 TILs 和抗 PD1 联合治疗在低 MSI 表达和 PDL1 阴性的转移性宫颈癌患者中的疗效。

方法

共 80 例患者接受 TILs 和抗 PD1 联合治疗，采用 Kaplan-Meier 分析评估无进展生存期（PFS）和总生存期（OS）。对单因素和多因素分析以确定先前描述的转移性宫颈癌患者预后的预测因素。

结果

客观缓解率为 25%，mPFS 和 mOS 分别为 6.1 个月和 11.3 个月。治疗效果受 TILs 的特征、HPV 感染以及治疗后发热的影响。

结论

总的来说，我们的结果表明 TILs 和抗 PD1 的联合治疗显著改善了转移性宫颈癌的预后。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/973f/7492938/c10b2b204363/JIR2020-8345235.005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/973f/7492938/10ce39a803cd/JIR2020-8345235.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/973f/7492938/ae3fb50b046c/JIR2020-8345235.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/973f/7492938/fce1efe36c97/JIR2020-8345235.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/973f/7492938/8c6acc5a1121/JIR2020-8345235.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/973f/7492938/c10b2b204363/JIR2020-8345235.005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/973f/7492938/10ce39a803cd/JIR2020-8345235.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/973f/7492938/ae3fb50b046c/JIR2020-8345235.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/973f/7492938/fce1efe36c97/JIR2020-8345235.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/973f/7492938/8c6acc5a1121/JIR2020-8345235.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/973f/7492938/c10b2b204363/JIR2020-8345235.005.jpg

相似文献

1
TILs and Anti-PD1 Therapy: An Alternative Combination Therapy for PDL1 Negative Metastatic Cervical Cancer.肿瘤浸润淋巴细胞（TILs）与抗 PD-1 治疗：PDL1 阴性转移性宫颈癌的一种替代联合治疗方法。
J Immunol Res. 2020 Sep 7;2020:8345235. doi: 10.1155/2020/8345235. eCollection 2020.
2
PD-L1 expression is associated with tumor infiltrating lymphocytes that predict response to NACT in squamous cell cervical cancer.PD-L1 表达与肿瘤浸润淋巴细胞相关，其可预测鳞状细胞宫颈癌对新辅助化疗的反应。
Virchows Arch. 2021 Mar;478(3):517-525. doi: 10.1007/s00428-020-02922-5. Epub 2020 Sep 11.
3
PD‑L1/PD‑1 blockade in breast cancer: The immunotherapy era (Review).PD-L1/PD-1 阻断在乳腺癌中的应用：免疫治疗时代（综述）。
Oncol Rep. 2021 Jan;45(1):5-12. doi: 10.3892/or.2020.7831. Epub 2020 Nov 3.
4
Anti-4-1BB×PDL1 Bispecific Antibody Reinvigorates Tumor-Specific Exhausted CD8+ T Cells and Enhances the Efficacy of Anti-PD1 Blockade.抗 4-1BB×PDL1 双特异性抗体使肿瘤特异性耗竭 CD8+ T 细胞重新焕发活力，并增强抗 PD1 阻断的疗效。
Clin Cancer Res. 2024 Sep 13;30(18):4155-4166. doi: 10.1158/1078-0432.CCR-23-2864.
5
PD1 protein expression in tumor infiltrated lymphocytes rather than PDL1 in tumor cells predicts survival in triple-negative breast cancer.肿瘤浸润淋巴细胞中的 PD1 蛋白表达而非肿瘤细胞中的 PDL1 预测三阴性乳腺癌的生存。
Cancer Biol Ther. 2018 May 4;19(5):373-380. doi: 10.1080/15384047.2018.1423919. Epub 2018 Feb 16.
6
Immune parameters associated with survival in metaplastic breast cancer.与化生性乳腺癌生存相关的免疫参数。
Breast Cancer Res. 2020 Aug 18;22(1):92. doi: 10.1186/s13058-020-01330-6.
7
Genomic profiling of advanced cervical cancer to predict response to programmed death-1 inhibitor combination therapy: a secondary analysis of the CLAP trial.晚期宫颈癌的基因组分析预测程序性死亡受体-1 抑制剂联合治疗的反应：CLAP 试验的二次分析。
J Immunother Cancer. 2021 May;9(5). doi: 10.1136/jitc-2020-002223.
8
Antibody targeting tumor-derived soluble NKG2D ligand sMIC reprograms NK cell homeostatic survival and function and enhances melanoma response to PDL1 blockade therapy.抗体靶向肿瘤来源的可溶性 NKG2D 配体 sMIC 重编程 NK 细胞的稳态存活和功能，并增强黑色素瘤对 PD-L1 阻断治疗的反应。
J Hematol Oncol. 2020 Jun 9;13(1):74. doi: 10.1186/s13045-020-00896-0.
9
CTLA-4 Synergizes With PD1/PD-L1 in the Inhibitory Tumor Microenvironment of Intrahepatic Cholangiocarcinoma.CTLA-4 与 PD1/PD-L1 在肝内胆管癌抑制性肿瘤微环境中协同作用。
Front Immunol. 2021 Aug 30;12:705378. doi: 10.3389/fimmu.2021.705378. eCollection 2021.
10
Predict progression free survival and overall survival using objective response rate for anti-PD1/PDL1 therapy development.使用抗 PD1/PDL1 治疗的客观缓解率预测无进展生存期和总生存期。
BMC Cancer. 2024 Jul 29;24(1):912. doi: 10.1186/s12885-024-12664-1.

引用本文的文献

1
Research progress on tumor-infiltrating lymphocyte therapy for cervical cancer.宫颈癌肿瘤浸润淋巴细胞治疗的研究进展
Front Immunol. 2025 May 19;16:1524842. doi: 10.3389/fimmu.2025.1524842. eCollection 2025.
2
Advances and Challenges in the Treatment of HPV-Associated Lower Genital Tract Cancers by Immune Checkpoint Blockers: Insights from Basic and Clinical Science.免疫检查点阻断剂治疗人乳头瘤病毒相关下生殖道癌的进展与挑战：基础与临床科学见解
Cancers (Basel). 2025 Apr 8;17(8):1260. doi: 10.3390/cancers17081260.
3
HPV-driven cancer: from epidemiology to the HPV-driven tumor board proposal, everything you wanted to know but were afraid to ask.

本文引用的文献

1
Tumor-infiltrating lymphocytes as a feasible adjuvant immunotherapy for osteosarcoma with a poor response to neoadjuvant chemotherapy.肿瘤浸润淋巴细胞作为一种可行的辅助免疫疗法，用于对新辅助化疗反应不佳的骨肉瘤。
Immunotherapy. 2020 Jun;12(9):641-652. doi: 10.2217/imt-2020-0107. Epub 2020 Jun 3.
2
Cancer statistics, 2020.癌症统计数据，2020 年。
CA Cancer J Clin. 2020 Jan;70(1):7-30. doi: 10.3322/caac.21590. Epub 2020 Jan 8.
3
Nivolumab in chemotherapy-resistant cervical cancer: report of a vulvitis as a novel immune-related adverse event and molecular analysis of a persistent complete response.
人乳头瘤病毒（HPV）驱动的癌症：从流行病学到HPV驱动的肿瘤专家委员会提案，你想知道但又不敢问的一切。
Clin Transl Oncol. 2025 Mar 6. doi: 10.1007/s12094-025-03868-3.
4
Prognostic significance of peripheral and tumor-infiltrating lymphocytes in newly diagnosed stage III/IV non-small-cell lung cancer.外周血及肿瘤浸润淋巴细胞在新诊断的Ⅲ/Ⅳ期非小细胞肺癌中的预后意义
Front Med (Lausanne). 2024 May 22;11:1349178. doi: 10.3389/fmed.2024.1349178. eCollection 2024.
5
Linking tumor immune infiltrate and systemic immune mediators to treatment response and prognosis in advanced cervical cancer.将肿瘤免疫浸润与全身免疫介质与晚期宫颈癌的治疗反应和预后联系起来。
Sci Rep. 2023 Dec 19;13(1):22634. doi: 10.1038/s41598-023-49441-2.
6
The abscopal effect of immune-radiation therapy in recurrent and metastatic cervical cancer: a narrative review.免疫-放疗在复发性和转移性宫颈癌中的远隔效应：叙述性综述。
Front Immunol. 2023 Jul 19;14:1201675. doi: 10.3389/fimmu.2023.1201675. eCollection 2023.
7
Clinical Trials of Cellular Therapies in Solid Tumors.实体瘤细胞疗法的临床试验
Cancers (Basel). 2023 Jul 19;15(14):3667. doi: 10.3390/cancers15143667.
8
Revisiting mechanisms of resistance to immunotherapies in metastatic clear-cell renal-cell carcinoma.重新审视转移性透明细胞肾细胞癌对免疫疗法的耐药机制。
Cancer Drug Resist. 2023 May 30;6(2):314-326. doi: 10.20517/cdr.2023.09. eCollection 2023.
9
Lighting Up the Fire in the Microenvironment of Cold Tumors: A Major Challenge to Improve Cancer Immunotherapy.点亮冷肿瘤微环境的“火”：提高癌症免疫治疗的一大挑战。
Cells. 2023 Jul 5;12(13):1787. doi: 10.3390/cells12131787.
10
Recent Advances in Cervical Cancer Management: A Review on Novel Prognostic Factors in Primary and Recurrent Tumors.宫颈癌管理的最新进展：原发性和复发性肿瘤新预后因素综述
Cancers (Basel). 2023 Feb 10;15(4):1137. doi: 10.3390/cancers15041137.
尼伏鲁单抗治疗化疗耐药性宫颈癌：一例新型免疫相关不良事件（外阴炎症）报告及持续性完全缓解的分子分析。
J Immunother Cancer. 2019 Oct 31;7(1):281. doi: 10.1186/s40425-019-0742-6.
4
Identification and transcriptome analysis of erythroblastic island macrophages.红细胞生成小岛巨噬细胞的鉴定和转录组分析。
Blood. 2019 Aug 1;134(5):480-491. doi: 10.1182/blood.2019000430. Epub 2019 May 17.
5
Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study.帕博利珠单抗治疗既往治疗的晚期宫颈癌的疗效和安全性：来自 II 期 KEYNOTE-158 研究的结果。
J Clin Oncol. 2019 Jun 10;37(17):1470-1478. doi: 10.1200/JCO.18.01265. Epub 2019 Apr 3.
6
PD-1/PD-L1 Inhibitors in Cervical Cancer.宫颈癌中的PD-1/PD-L1抑制剂
Front Pharmacol. 2019 Feb 1;10:65. doi: 10.3389/fphar.2019.00065. eCollection 2019.
7
A Phase II Study of Tumor-infiltrating Lymphocyte Therapy for Human Papillomavirus-associated Epithelial Cancers.肿瘤浸润淋巴细胞治疗人乳头瘤病毒相关上皮性肿瘤的 II 期研究。
Clin Cancer Res. 2019 Mar 1;25(5):1486-1493. doi: 10.1158/1078-0432.CCR-18-2722. Epub 2018 Dec 5.
8
Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes in Advanced Melanoma Patients.肿瘤浸润淋巴细胞过继细胞疗法治疗晚期黑色素瘤患者。
J Immunol Res. 2018 Mar 19;2018:3530148. doi: 10.1155/2018/3530148. eCollection 2018.
9
Cervical cancer - State of the science: From angiogenesis blockade to checkpoint inhibition.宫颈癌——科学现状：从血管生成阻断到检查点抑制。
Gynecol Oncol. 2018 Mar;148(3):609-621. doi: 10.1016/j.ygyno.2018.01.009. Epub 2018 Feb 3.
10
Neoadjuvant Chemotherapy Followed by Radical Surgery Versus Concomitant Chemotherapy and Radiotherapy in Patients With Stage IB2, IIA, or IIB Squamous Cervical Cancer: A Randomized Controlled Trial.新辅助化疗后行根治性手术与同期放化疗治疗 IB2 期、IIA 期或 IIB 期鳞癌宫颈癌患者的随机对照研究。
J Clin Oncol. 2018 Jun 1;36(16):1548-1555. doi: 10.1200/JCO.2017.75.9985. Epub 2018 Feb 12.